Team Vroomy is gearing up to race in Type One’s family-friendly, four-mile Renegade Run Obstacle Course Race on October 20, 2019, to raise awareness and funds for type 1 diabetes research at Massachusetts General Hospital (MGH), and to provide assistance for diabetes management and treatment to those living with the disease.
Led by Hingham residents Ashley and Robert Windsor, Team Vroomy has been participating in Renegade Run each year in support of Type One’s mission. Their son, Vroomy (now six-years-old) was diagnosed with type 1 diabetes at the age of two.
“The first Renegade Run our family did was prior to Vroomy’s diagnosis. The race is in Hingham and we wanted to support those in our community. Then, Vroomy was diagnosed and it affected us directly,” explained Ashley Windsor. “Vroomy is happy and doing well. Type 1 diabetes has not slowed him down at all! After his diagnosis, Team Vroomy was formed with four participants – my husband and family members – and our team has grown ever since.”
In 2017, Team Vroomy had 44 participants in support of Type One and Vroomy and last year, they had an impressive 77 participants (30 of them were children). The Windors hope to have 100 runners in this year’s race. Team Vroomy is easy to spot on the course, with their signature logo on their custom t-shirts and headbands. “We are so excited for this year’s Renegade Run! Team Vroomy is hoping to break the 100 person mark,” said Windsor.
She continued, “We’ll do anything we can to support Renegade Run and raise awareness and research funds for T1D. Our family is thrilled to do this race every year for as long type 1 exists. We are Team Vroomy!”
Event To Cure Type 1 Diabetes
Type One’s Renegade Run Obstacle Course Race will be held Sunday, October 20, 2019 at Bare Cove Park in Hingham. The family-friendly race begins at 9:00 AM and is open to the public. It will feature a course through four miles of paved trails and wooded terrain with over 25 obstacles including monkey bars to cross, walls and cargo nets to climb, and tunnels to crawl through. Event activities include a Mini Renegade Run for kids, live concert, food trucks, vendors and beer tent.
Funds raised will support Type One’s mission to raise funds and awareness for type 1 diabetes research at Massachusetts General Hospital (MGH). To date, Type One’s annual Renegade Run has generated tens of thousands of dollars to support the Faustman Lab at MGH which is focused on discovering and developing new treatments for type 1 diabetes, a vaccine for the reversal of long-term type 1 diabetes and other autoimmune diseases.
In addition to supporting the Faustman Lab at MGH, Type One donation and fundraising platforms help provide scholarships to local children with type 1 diabetes to attend type 1 diabetes camp, as well as providing qualifying recipients with assistance for diabetes management and treatment.
There will be free t-shirts and finisher medals for those who complete the Renegade Run, a complimentary beer for those 21+, free parking, no spectator fee, and many other surprises.
To register for the 8th Annual Renegade Run Obstacle Course Race, visit https://typeonerenegaderun.com/register/. Unable to attend on race day? Register as a Virtual Runner.
To create a Renegade Run fundraising page, or to start a fundraiser or to make a donation, visit https://typeonerenegaderun.com/fundraise/
About Type One
Type One, a 501(c)(3) nonprofit organization, recognizes a world free of type 1 diabetes (T1D) and is dedicated to that future by raising public awareness and funds toward a cure through research. Type One was founded in 2012 by a group of South Shore residents to support their friend Tyson Sunnerberg, who was diagnosed with type 1 diabetes, an autoimmune disease in which a person’s pancreas stops producing insulin, when he was 21 years old. On November 25, 2012, the first ever Renegade Run Obstacle Course Race was held raising awareness and funds toward a cure.
To date, Type One’s Renegade Run has generated tens of thousands of dollars to support the Faustman Lab at MGH, which is run by Dr. Denise Faustman, director of the Immunobiology Laboratory at MGH, and is focused on discovering and developing new treatments for type 1 diabetes and other autoimmune diseases. Dr. Faustman is currently leading a human clinical trial program testing the efficacy of the BCG (bacille Calmette-Guerin) vaccine for reversal of long-term type 1 diabetes. For more information on the Faustman Lab at MGH and type 1 diabetes, visit www.faustmanlab.org.